AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06420401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
Study NCT06540313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.
Study NCT05734976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
Study NCT05734976 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
Study NCT06461676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventrix Bio Extracellular Matrix
Description: VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
Study NCT05155020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
Study NCT05155020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
Study NCT05155020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
Study NCT05155020 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
Study NCT06514209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Description: The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
Study NCT06515093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SanoGraft
Description: single layer amnion amnion-derived allograft
Study NCT06515093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PelloGraft
Description: dual layer amnion/chorion-derived allograft
Study NCT05273398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal diazepam
Description: Nasal administration of diazepam
Study NCT06365580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrated orally.
Study NCT05848739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST316
Description: IV
Study NCT05848739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen & bevacizumab
Description: FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg.
Study NCT05848739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 5 mg once a day for the first 21 days of a 28-day cycle
Study NCT06082531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injection
Description: The control group was injected into the joint cavity with sodium hyaluronate injection..
Study NCT05140863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
Study NCT05140863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
Study NCT05140863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: Placebo, orally twice a day, treatment period; 12-weeks fixed dose
Study NCT05848739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonsurf & bevacizumab
Description: Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine Injectable Solution
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05413902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study NCT05203588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml Injectable Solution [Prolia]
Description: Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
Study NCT05203588 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: calcium and vitamin D
Description: calcium (≥1·0 g) and vitamin D (≥400 IU).
Study NCT05203588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium and vitamin D
Description: calcium (≥1·0 g) and vitamin D (≥400 IU).
Study NCT06669260 — intervention group
Intervention type: PROCEDURE
Intervention: TEThA technique
Description: Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.
Study NCT06008977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Test
Description: Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
Study NCT04637685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centurion Phacoemulsification System
Description: Infusion Pressure
Study NCT05200806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-Narcotic ERAS Post-Operative Pain Management
Description: As described previously.
Study NCT06237699 — intervention group
Intervention type: OTHER
Intervention: Digital ICU diary
Description: A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
Study NCT04835415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral retrolaminar block
Description: in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
Study NCT04835415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
Study NCT05107154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioural Therapy
Description: DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
Study NCT04552080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
Study NCT04552080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
Study NCT06241651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.
Study NCT06241651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
Study NCT05282355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.
Study NCT05282355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.
Study NCT04934111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP-nCOV saRNA-02 Vaccine
Description: a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
Study NCT05815186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
Study NCT05815186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
Study NCT06533618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
Study NCT04968067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App group
Description: In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
Study NCT04968067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nursing telephone advice (NTA) group
Description: All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
Study NCT06701019 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview/focus group discussion
Description: All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option.
Study NCT06383143 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06567288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spencer mscle energy technique
Description: The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
Study NCT05074602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8008
Description: Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
Study NCT05074602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
Study NCT05969028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: igel
Description: First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.
Study NCT05969028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Rate
Description: Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
Study NCT05643131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyivy Intravaginal Device
Description: Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
Study NCT05620459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge augmentation using chin bone ring with simultaneous implant placement
Description: surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
Study NCT05764200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two day supplementation of a complex fiber mixture
Description: Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
Study NCT05764200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
Study NCT06568120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dragon themed nebulizer masks
Description: This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
Study NCT06529458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 Group
Description: The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.